1. Executive Summary
2. Global Childhood Vaccines Market Introduction
2.1. Global Childhood Vaccines Market – Taxonomy
2.2. Global Childhood Vaccines Market –Definitions
2.2.1. Vaccine Type
2.2.2. Application
2.2.3. Application
2.2.4. Composition
2.2.5. End-User
3. Global Childhood Vaccines Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Childhood Vaccines Market Dynamic Factors – Impact Analysis
3.6. Global Childhood Vaccines Market – Regulations
3.6.1. U.S.
3.6.2. Europe
3.7. Global Childhood Vaccines Market –Trends
4. Global Childhood Vaccines Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024
4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Global Childhood Vaccines Market, By Treatment Type, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
5.1. Inactivated Vaccines
5.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Attenuated Vaccines
5.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Toxoid Vaccines
5.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Subunit Vaccines
5.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Conjugate Vaccines
5.5.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
5.6. Others
5.6.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.6.3. Market Opportunity Analysis
6. Global Childhood Vaccines Market, By Application, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
6.1. Oral
6.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Intramuscular
6.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Intradermal
6.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Subcutaneous
6.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
6.5. Intranasal
6.5.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.5.3. Market Opportunity Analysis
7. Global Childhood Vaccines Market, By Application, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
7.1. Diphtheria
7.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Pertussis
7.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Tetanus
7.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Polio
7.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
7.5. Measles
7.5.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.5.3. Market Opportunity Analysis
7.6. Hepatitis-B
7.6.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
7.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.6.3. Market Opportunity Analysis
7.7. Others
7.7.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
7.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.7.3. Market Opportunity Analysis
8. Global Childhood Vaccines Market Forecast, By Composition, 2013 – 2017 and Forecast, 2018 – 2024
8.1. Mono Vaccines
8.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Combination Vaccines
8.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
9. Global Childhood Vaccines Market Forecast, By Distribution Channel, 2013 – 2017 and Forecast, 2018 – 2024
9.1. Hospitals
9.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.1.3. Market Opportunity Analysis
9.2. Clinics
9.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.2.3. Market Opportunity Analysis
9.3. Vaccination Centres
9.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.3.3. Market Opportunity Analysis
10. Global Childhood Vaccines Market Forecast, By Region, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
10.1. North America
10.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
10.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
10.1.3. Market Opportunity Analysis
10.2. Europe
10.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
10.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
10.2.3. Market Opportunity Analysis
10.3. Asia-Pacific
10.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
10.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
10.3.3. Market Opportunity Analysis
10.4. Latin America
10.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
10.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
10.4.3. Market Opportunity Analysis
10.5. Middle East and Africa
10.5.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
10.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
10.5.3. Market Opportunity Analysis
10.6. Global Childhood Vaccines Market – Opportunity Analysis Index, By Vaccine Type, By Route of Administration, By Application, By Composition, By End-User and Region, 2018 – 2024
11. North America Childhood Vaccines Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
11.1. Vaccine Type Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Inactivated Vaccines
11.1.2. Attenuated Vaccines
11.1.3. Toxoid Vaccines
11.1.4. Subunit Vaccines
11.1.5. Conjugate Vaccines
11.1.6. Others
11.2. Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.2.1. Oral
11.2.2. Intramuscular
11.2.3. Intradermal
11.2.4. Subcutaneous
11.2.5. Intranasal
11.3. Application Type Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.3.1. Diphtheria
11.3.2. Pertussis
11.3.3. Tetanus
11.3.4. Polio
11.3.5. Measles
11.3.6. Hepatitis-B
11.3.7. Others
11.4. Composition Type Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.4.1. Mono Vaccines
11.4.2. Combinition Vaccines
11.5. End-User Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.5.1. Hospitals
11.5.2. Clinics
11.5.3. Vaccination Centres
11.6. Country Analysis 2016 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
11.6.1. US
11.6.2. Canada
11.7. North America Childhood Vaccines Market – Opportunity Analysis Index, By Vaccine Type, By Route of Administration, By Application, By Composition, By End-User and Country, 2018 – 2024
11.8. North America Childhood Vaccines Market Dynamics – Trends
12. Europe Childhood Vaccines Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
12.1. Vaccine Type Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Inactivated Vaccines
12.1.2. Attenuated Vaccines
12.1.3. Toxoid Vaccines
12.1.4. Subunit Vaccines
12.1.5. Conjugate Vaccines
12.1.6. Others
12.2. Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.2.1. Oral
12.2.2. Intramuscular
12.2.3. Intradermal
12.2.4. Subcutaneous
12.2.5. Intranasal
12.3. Application Type Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.3.1. Diphtheria
12.3.2. Pertussis
12.3.3. Tetanus
12.3.4. Polio
12.3.5. Measles
12.3.6. Hepatitis-B
12.3.7. Others
12.4. Composition Type Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.4.1. Mono Vaccines
12.4.2. Combinition Vaccines
12.5. End-User Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.5.1. Hospitals
12.5.2. Clinics
12.5.3. Vaccination Centres
12.6. Country Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
12.6.1. Germany
12.6.2. UK
12.6.3. France
12.6.4. Spain
12.6.5. Italy
12.6.6. Russia
12.6.7. Poland
12.6.8. Rest of Europe
12.7. Europe Childhood Vaccines Market – Opportunity Analysis Index, By Vaccine Type, By Route of Administration, By Application, By Composition, By End-User and Country, 2018 – 2024
12.8. Europe Childhood Vaccines Market Dynamics – Trends
13. Asia-Pacific Childhood Vaccines Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
13.1. Vaccine Type Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1. Inactivated Vaccines
13.1.2. Attenuated Vaccines
13.1.3. Toxoid Vaccines
13.1.4. Subunit Vaccines
13.1.5. Conjugate Vaccines
13.1.6. Others
13.2. Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.2.1. Oral
13.2.2. Intramuscular
13.2.3. Intradermal
13.2.4. Subcutaneous
13.2.5. Intranasal
13.3. Application Type Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.3.1. Diphtheria
13.3.2. Pertussis
13.3.3. Tetanus
13.3.4. Polio
13.3.5. Measles
13.3.6. Hepatitis-B
13.3.7. Others
13.4. Composition Type Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.4.1. Mono Vaccines
13.4.2. Combinition Vaccines
13.5. End-User Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.5.1. Hospitals
13.5.2. Clinics
13.5.3. Vaccination Centres
13.6. Country Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
13.6.1. Japan
13.6.2. China
13.6.3. India
13.6.4. ASEAN
13.6.5. Australia & New Zealand
13.6.6. Rest of Asia-Pacific
13.7. Asia-Pacific Childhood Vaccines Market – Opportunity Analysis Index, By Vaccine Type, By Route of Administration, By Application, By Composition, By End-User and Country, 2018 – 2024
13.8. Asia-Pacific Childhood Vaccines Market Dynamics – Trends
14. Latin America Childhood Vaccines Market Analysis, 2012 – 2012 – 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
14.1. Vaccine Type Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
14.1.1. Inactivated Vaccines
14.1.2. Attenuated Vaccines
14.1.3. Toxoid Vaccines
14.1.4. Subunit Vaccines
14.1.5. Conjugate Vaccines
14.1.6. Others
14.2. Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.2.1. Oral
14.2.2. Intramuscular
14.2.3. Intradermal
14.2.4. Subcutaneous
14.2.5. Intranasal
14.3. Application Type Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.3.1. Diphtheria
14.3.2. Pertussis
14.3.3. Tetanus
14.3.4. Polio
14.3.5. Measles
14.3.6. Hepatitis-B
14.3.7. Others
14.4. Composition Type Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.4.1. Mono Vaccines
14.4.2. Combinition Vaccines
14.5. End-User Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.5.1. Hospitals
14.5.2. Clinics
14.5.3. Vaccination Centres
14.6. Country Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Argentina
14.6.4. Venezuela
14.6.5. Rest of Latin America
14.7. Latin America Childhood Vaccines Market – Opportunity Analysis Index, By Vaccine Type, By Route of Administration, By Application, By Composition, By End-User and Country, 2018 – 2024
14.8. Latin America Childhood Vaccines Market Dynamics – Trends
15. Middle East and Africa Childhood Vaccines Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
15.1. Vaccine Type Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
15.1.1. Inactivated Vaccines
15.1.2. Attenuated Vaccines
15.1.3. Toxoid Vaccines
15.1.4. Subunit Vaccines
15.1.5. Conjugate Vaccines
15.1.6. Others
15.2. Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
15.2.1. Oral
15.2.2. Intramuscular
15.2.3. Intradermal
15.2.4. Subcutaneous
15.2.5. Intranasal
15.3. Application Type Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
15.3.1. Diphtheria
15.3.2. Pertussis
15.3.3. Tetanus
15.3.4. Polio
15.3.5. Measles
15.3.6. Hepatitis-B
15.3.7. Others
15.4. Composition Type Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
15.4.1. Mono Vaccines
15.4.2. Combinition Vaccines
15.5. End-User Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
15.5.1. Hospitals
15.5.2. Clinics
15.5.3. Vaccination Centres
15.6. Country Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
15.6.1. Gulf Cooperation Council (GCC) Countries
15.6.2. Israel
15.6.3. South Africa
15.6.4. Rest of MEA
15.7. MEA Childhood Vaccines Market – Opportunity Analysis Index, By Vaccine Type, By Route of Administration, By Application, By Composition, By End-User and Country, 2018 – 2024
15.8. MEA Childhood Vaccines Market Dynamics – Trends
16. Competition Landscape
16.1. Strategic Dashboard of Top Market Players
16.2. Company Profiles (Introduction, Financial Analysis, Treatment Type & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
16.2.1. AstraZeneca (UK)
16.2.2. Bayer AG (Germany)
16.2.3. Daiichi Sankyo Company Ltd (Japan)
16.2.4. Eisai Co Ltd (Japan)
16.2.5. GlaxoSmithKline Plc. (UK)
16.2.6. Grupo Praxis Pharmaceutical SA (Spain)
16.2.7. KaloBios Pharmaceuticals, Inc. (U.S.)
16.2.8. Kancera AB (Sweden)
16.2.9. Novartis AG (Switzerland)
16.2.10. Laboratorio Elea S.A.C.I.F. y A (Argentina)
16.2.11. Oblita Therapeutics BVBA (Belgium)
16.2.12. Sanofi (France
17. Research Methodology
18. Key Assumptions and Acronyms